Inventia recalls 13,567 bottles of chlorthalidone

Inventia Healthcare has recalled 13,567 bottles of 25-milligram chlorthalidone tablets after the medication failed dissolution specifications, according to a U.S. Food and Drug Administration enforcement report. The nationwide recall, initiated in September, covers batch RISA24002 and carries a Class II designation from the agency. The affected bottles contain 100 tablets and are identified by National Drug Code 6498059901, with an expiration date of April 2027. The FDA’s enforcement report says the quality issue was failed dissolution testing. If tablets do not release their active ingredient as intended, the medication may be less effective, according to the recall accounts. Chlorthalidone is a diuretic used to treat high blood pressure and fluid retention. The FDA defines a Class II recall as one involving a product that may cause temporary or medically reversible health consequences, while the likelihood of serious harm is considered remote. The classification describes the agency’s assessment of risk; it does not establish that patients have experienced harm. Four of the five reviewed accounts describe the September action and its 13,567-bottle quantity.